Article Text

other Versions

PDF
Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor-2 antagonist in painful knee osteoarthritis compared to magnetic resonance imaging
  1. IH Song (in-ho.song{at}charite.de)
  1. Rheumatology, Charité, Berlin, Germany
    1. C E Althoff (christian.althoff{at}charite.de)
    1. Radiology Department, Charité, Germany, Germany
      1. KG Hermann (kgh{at}charite.de)
      1. Radiology Department, Charité, Germany, Germany
        1. A K Scheel (ascheel{at}gwdg.de)
        1. Dept. of Nephrology and Rheumatology, Frankfurt a.M., Germany
          1. T Knetsch (torsten.knetsch{at}esaote.de)
          1. Esaote, Neufahrn, Germany
            1. GR Burmester (gerd.burmester{at}charite.de)
            1. Rheumatology, Charité, Berlin, Germany
              1. M Backhaus (marina.backhaus{at}charite.de)
              1. Rheumatology, Charité, Berlin, Germany

                Abstract

                Objectives: Evaluation of contrast-enhanced ultrasound (CE-US) as a monitoring tool to assess hypervascularisation of synovial processes in knee osteoarthritis (OA) treated with intraarticular injections of the bradykinin-receptor-2 antagonist icatibant compared to contrast-enhanced magnetic resonance imaging (CE-MRI).

                Patients and Methods: In a randomised, double-blind, placebo-controlled trial, 41 patients with painful knee OA underwent US (12.5 MHz for B-mode and 3-8 MHz for CE-US), and 36 of the patients underwent additional MRI (0.2T) at baseline and after 3 injections of the study drug (after a mean of 22.2 days). Fifteen patients received placebo (group A), 12 500μg icatibant (group B) and 14 2000μg icatibant (group C). Pain and the synovial process (B-mode, Power Doppler- US [PD-US], CE-US, CE-MRI) were assessed at both time points.

                Results: At baseline, the placebo group showed more activity in terms of effusion in the superior and lateral recess in ultrasound as well as in PD-US in the lateral recess. Pain improved significantly in all subgroups. Effect sizes were 0.43 (pain at rest) and 0.52 (pain during activity) in group B versus 0.48 and 1.11 in group C. There was no change of US and MRI parameters. We found moderate to good correlation (r) and kappa values (k) for effusion in the superior recess (r= 0.591, k= 0.453), effusion in the lateral recess (r= 0.304, k= 0.440), and contrast enhancement (r= 0.601, k= 0.242) between US and MRI.

                Conclusion: Our results show that CE-US and CE-MRI have good agreement in assessing inflammatory changes in knee OA. For the 41 OA patients, an analgesic effect of icatibant could clearly be shown, especially for pain during activity in the high dose icatibant group. However, we could not find an anti-inflammatory effect of icatibant by CE-US compared to CE-MRI.

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.